<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biomotion Sciences Ordinary Shares — News on 6ix</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares</link>
<description>Latest news and press releases for Biomotion Sciences Ordinary Shares on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biomotion-sciences-ordinary-shares" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c19178dffbe2df118f53.webp</url>
<title>Biomotion Sciences Ordinary Shares</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares</link>
</image>
<item>
<title>Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-successful-submission-of-phase-23-clinical-trial-application-to-germanys-bfarm-for-sil204-in-kras-driven-locally-advanced-pancreatic-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-successful-submission-of-phase-23-clinical-trial-application-to-germanys-bfarm-for-sil204-in-kras-driven-locally-advanced-pancreatic-cancer</guid>
<pubDate>Tue, 28 Apr 2026 12:45:00 GMT</pubDate>
<description>CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU programGrand Cayman, Cayman Islands, April 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the recent successful submission of a Clinical Trial Application</description>
</item>
<item>
<title>Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-receives-approval-from-israeli-ministry-of-health-to-initiate-phase-23-clinical-trial-of-sil204-in-locally-advanced-pancreatic-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-receives-approval-from-israeli-ministry-of-health-to-initiate-phase-23-clinical-trial-of-sil204-in-locally-advanced-pancreatic-cancer</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated</description>
</item>
<item>
<title>Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including</description>
</item>
<item>
<title>Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-urges-shareholders-to-vote-ahead-of-march-16-extraordinary-general-meeting-8</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-urges-shareholders-to-vote-ahead-of-march-16-extraordinary-general-meeting-8</guid>
<pubDate>Thu, 05 Mar 2026 13:00:00 GMT</pubDate>
<description>Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the upcoming Extraordinary General Meeting of Shareholders (the "EGM"), scheduled to be held on March 16, 2026. At the EGM, shareholders will be asked to vote on proposals relating to: Authorized Share Capital Increase Proposal: An increase to the authorized share capital of the Company by</description>
</item>
<item>
<title>Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-attend-7th-annual-133000881</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-attend-7th-annual-133000881</guid>
<pubDate>Wed, 21 Jan 2026 13:30:00 GMT</pubDate>
<description>Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA. The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic,</description>
</item>
<item>
<title>Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-releases-ceo-letter-123000955</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-releases-ceo-letter-123000955</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated $30+ Billion Global KRAS-Driven Cancer Market with Pan-KRAS Therapeutic Platform Initiation of Phase 2/3 Clinical Trial in LAPC Planned for H1 2026 Following Positive Regulatory Feedback and Successful Toxicology Studies Grand Cayman, Cayman Islands, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Silexion Therape</description>
</item>
<item>
<title>Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-submission-phase-134000813</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-submission-phase-134000813</guid>
<pubDate>Tue, 16 Dec 2025 13:40:00 GMT</pubDate>
<description>Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies, positive German regulatory feedback, and strong preclinical data demonstrating up to 99.7% cancer cell inhibition Regulatory filings in Germany and the EU are planned for Q1 2026, with U.S. expansion anticipated following the safety run-in Grand Cayman, Cayman Islands, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sil</description>
</item>
<item>
<title>Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-receives-positive-feedback-130000712</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-receives-positive-feedback-130000712</guid>
<pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
<description>Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the end of Q4 2025 and in Germany during Q1 2026 GRAND CAYMAN, Cayman Islands, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today anno</description>
</item>
<item>
<title>Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-present-noble-capital-123000843</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-present-noble-capital-123000843</guid>
<pubDate>Wed, 26 Nov 2025 12:30:00 GMT</pubDate>
<description>Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21). Presentation details:Type: Company presentationDate: December 3, 2025Time: 2:30 – 2:55pm ETSpeakers: Ilan Hadar, Chief Executive Officer and Mirit Horenshte</description>
</item>
<item>
<title>Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-successfully-completes-toxicology-141500526</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-successfully-completes-toxicology-141500526</guid>
<pubDate>Tue, 25 Nov 2025 14:15:00 GMT</pubDate>
<description>Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on track to initiate Phase 2/3 clinical trial in locally advanced pancreatic cancer in Q2 2026 Grand Cayman, Cayman Islands, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference (RNA</description>
</item>
<item>
<title>Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-reports-third-quarter-140000715</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-reports-third-quarter-140000715</guid>
<pubDate>Wed, 12 Nov 2025 14:00:00 GMT</pubDate>
<description>Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell lines, highlighting potential effectiveness against five KRAS-driven cancer types Successfully raised over $9 million during the third quarter, significantly strengthening the Company’s balance sheet Grand Cayman, Cayman Islands, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:</description>
</item>
<item>
<title>Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-positive-human-124000744</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-positive-human-124000744</guid>
<pubDate>Tue, 30 Sep 2025 12:40:00 GMT</pubDate>
<description>New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer activity expands potential therapeutic reach of SIL204 GRAND CAYMAN, Cayman Islands, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for</description>
</item>
<item>
<title>Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-regains-compliance-nasdaq-124500239</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-regains-compliance-nasdaq-124500239</guid>
<pubDate>Thu, 25 Sep 2025 12:45:00 GMT</pubDate>
<description>Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital MarketGRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confir</description>
</item>
<item>
<title>Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-pricing-6-131700488</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-pricing-6-131700488</guid>
<pubDate>Thu, 11 Sep 2025 13:17:00 GMT</pubDate>
<description>Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 1,500,000 of the Company’s ordinary shares (or ordinary share equivalents), series A warrants to purchase up to 1,500,000 ordinary shares and series B warrants to purchase up to 1,500,000 ordinary shar</description>
</item>
<item>
<title>Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-reports-positive-preclinical-110000405</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-reports-positive-preclinical-110000405</guid>
<pubDate>Thu, 11 Sep 2025 11:00:00 GMT</pubDate>
<description>New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further Validation of the Systemic Component of a Dual-Route Administration Strategy Enabeling Potential Targeting of Both Primary Tumors and Metastatic Disease Silexion Remains on Track for Phase 2/3 Trial Initiation in H1 2026 Following Planned Q4 2025 and Q1 2026 Regulatory Submissions GRAND CAYMAN, Cayman Island</description>
</item>
<item>
<title>Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-selection-contract-132500165</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-selection-contract-132500165</guid>
<pubDate>Thu, 04 Sep 2025 13:25:00 GMT</pubDate>
<description>Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026 Following Q4 2025 and Q1 2026 Regulatory Submissions CRO Brings Over 28 Years of Drug Development Experience and Proven Phase 3 Oncology Trial Expertise to Support Upcoming Trial GRAND CAYMAN, Cayman Islands, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or</description>
</item>
<item>
<title>Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-present-upcoming-27th-124500681</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-present-upcoming-27th-124500681</guid>
<pubDate>Tue, 02 Sep 2025 12:45:00 GMT</pubDate>
<description>Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that senior management will be presenting at the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-10, 2025, at the Lotte New York Palace Hotel, New York City. Silexion's company presentation will take place</description>
</item>
<item>
<title>Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-reports-second-quarter-120000858</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-reports-second-quarter-120000858</guid>
<pubDate>Tue, 12 Aug 2025 12:00:00 GMT</pubDate>
<description>Continued advancement of SIL204 preclinical program with strong efficacy data across multiple KRAS-driven cancer types; company strengthened financial position and maintains progress toward clinical trialsGRAND CAYMAN, Cayman Islands, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the sec</description>
</item>
<item>
<title>Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-exercise-warrants-000000174</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-exercise-warrants-000000174</guid>
<pubDate>Fri, 01 Aug 2025 00:00:00 GMT</pubDate>
<description>Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 p</description>
</item>
<item>
<title>Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation</title>
<link>https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-preclinical-data-135500968</link>
<guid isPermaLink="true">https://6ix.com/company/biomotion-sciences-ordinary-shares/news/silexion-therapeutics-announces-preclinical-data-135500968</guid>
<pubDate>Thu, 31 Jul 2025 13:55:00 GMT</pubDate>
<description>New Results Reveal Unprecedented Inhibition Rates and First Evidence of SIL204's Efficacy Against Previously Untested KRAS Q61H Mutation in Human Cancer Cells, Significantly Expanding its Pan-KRAS Potential; Company on track for the initiation of a Phase 2/3 clinical trial in Q2 2026Grand Cayman, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-d</description>
</item>
</channel>
</rss>